{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:58:48Z","timestamp":1793109528208,"version":"4.5.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijbiomac.2023.125514","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T22:05:15Z","timestamp":1687385115000},"page":"125514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A roadmap for developing Venezuelan equine encephalitis virus (VEEV) vaccines: Lessons from the past, strategies for the future"],"prefix":"10.1016","volume":"245","author":[{"given":"Lulu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7837","key":"10.1016\/j.ijbiomac.2023.125514_bb0005","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41586-020-2915-3","article-title":"LDLRAD3 is a receptor for Venezuelan equine encephalitis virus","volume":"588","author":"Ma","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1086\/382281","article-title":"Aerosol infection of cynomolgus macaques with enzootic strains of Venezuelan equine encephalitis viruses","volume":"189","author":"Reed","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0015","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1128\/JVI.02881-12","article-title":"Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation","volume":"87","author":"Atasheva","year":"2013","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0020","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/fvl.11.50","article-title":"Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella","volume":"6","author":"Aguilar","year":"2011","journal-title":"Futur. Virol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3201\/eid2704.202676","article-title":"Venezuelan equine encephalitis complex alphavirus in bats, French Guiana","volume":"27","author":"Fischer","year":"2021","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-020-00360-4","article-title":"Venezuelan equine encephalitis virus: the problem is not over for tropical America","volume":"19","author":"Guzm\u00e1n-Ter\u00e1n","year":"2020","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125514_bb0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jmedent\/42.5.857","article-title":"Susceptibility of Psorophora confinnis (Diptera: Culicidae) to infection with epizootic (subtype IC) and enzootic (subtype ID) Venezuelan equine encephalitis viruses","volume":"42","author":"Ortiz","year":"2005","journal-title":"J. Med. Entomol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1874357901812010080","article-title":"Zoonotic viral diseases of equines and their impact on human and animal health","volume":"12","author":"Kumar","year":"2018","journal-title":"Open Virol. J."},{"issue":"9025","key":"10.1016\/j.ijbiomac.2023.125514_bb0045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(96)02275-1","article-title":"Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America","volume":"348","author":"Weaver","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/v11020164","article-title":"Current understanding of the molecular basis of Venezuelan equine encephalitis virus pathogenesis and vaccine development","volume":"11","author":"Sharma","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4269\/ajtmh.2007.77.176","article-title":"Infection and dissemination of Venezuelan equine encephalitis virus in the epidemic mosquito vector, Aedes taeniorhynchus","volume":"77","author":"Smith","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.virol.2007.10.011","article-title":"Venezuelan equine encephalitis virus in the mosquito vector Aedes taeniorhynchus: infection initiated by a small number of susceptible epithelial cells and a population bottleneck","volume":"372","author":"Smith","year":"2008","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/v15020417","article-title":"Arboviruses in mammals in the neotropics: a systematic review to strengthen epidemiological monitoring strategies and conservation medicine","volume":"15","author":"Garc\u00eda-Romero","year":"2023","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.125514_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/v9100279","article-title":"Venezuelan equine encephalitis virus capsid\u2014the clever caper","volume":"9","author":"Lundberg","year":"2017","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine encephalitis","volume":"49","author":"Weaver","year":"2004","journal-title":"Annu. Rev. Entomol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/vaccines8020273","article-title":"Vaccine advances against venezuelan, eastern, and western equine encephalitis viruses","volume":"8","author":"Stromberg","year":"2020","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0085","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmv.1890380414","article-title":"Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine","volume":"38","author":"Engler","year":"1992","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125514_bb0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.vaccine.2010.11.033","article-title":"Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development","volume":"29","author":"Sharma","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0095","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/v14020272","article-title":"Inactivation of Venezuelan equine encephalitis virus genome using two methods","volume":"14","author":"Behnia","year":"2022","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168012","article-title":"Self-inhibited state of Venezuelan equine encephalitis virus (VEEV) nsP2 cysteine protease: a crystallographic and molecular dynamics analysis","volume":"435","author":"Hoffka","year":"2023","journal-title":"J. Mol. Biol."},{"issue":"19","key":"10.1016\/j.ijbiomac.2023.125514_bb0105","doi-asserted-by":"crossref","first-page":"9532","DOI":"10.1128\/JVI.75.19.9532-9537.2001","article-title":"Venezuelan equine encephalomyelitis virus structure and its divergence from old world alphaviruses","volume":"75","author":"Paredes","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0110","series-title":"Genetic Determinants of Venezuelan Equine Encephalitis Emergence","author":"Weaver","year":"2004"},{"issue":"12","key":"10.1016\/j.ijbiomac.2023.125514_bb0115","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3201\/eid1012.040393","article-title":"Venezuelan equine encephalitis virus, southern Mexico","volume":"10","author":"Estrada-Franco","year":"2004","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/vim.2006.0090","article-title":"Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells","volume":"20","author":"Nishimoto","year":"2007","journal-title":"Viral Immunol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0125","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/jvi.70.6.3781-3787.1996","article-title":"A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge","volume":"70","author":"Davis","year":"1996","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.ijbiomac.2023.125514_bb0130","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.3390\/ijms21207686","article-title":"Specificity studies of the Venezuelan equine encephalitis virus non-structural protein 2 protease using recombinant fluorescent substrates","volume":"21","author":"Boz\u00f3ki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1107\/S1744309106014667","article-title":"Purification, crystallization and X-ray diffraction analysis of the C-terminal protease domain of Venezuelan equine encephalitis virus nsP2","volume":"62","author":"Russo","year":"2006","journal-title":"Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun."},{"issue":"18","key":"10.1016\/j.ijbiomac.2023.125514_bb0140","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1038\/emboj.2011.261","article-title":"4.4 \u00c5 cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus","volume":"30","author":"Zhang","year":"2011","journal-title":"EMBO J."},{"issue":"7882","key":"10.1016\/j.ijbiomac.2023.125514_bb0145","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41586-021-03909-1","article-title":"Structure of Venezuelan equine encephalitis virus with its receptor LDLRAD3","volume":"598","author":"Ma","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0150","article-title":"Innate immune evasion by alphaviruses","volume":"5280","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"7882","key":"10.1016\/j.ijbiomac.2023.125514_bb0155","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41586-021-03963-9","article-title":"Structure of Venezuelan equine encephalitis virus in complex with the LDLRAD3 receptor","volume":"598","author":"Basore","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ijbiomac.2023.125514_bb0160","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.tim.2020.10.011","article-title":"Host factors and pathways involved in the entry of mosquito-borne alphaviruses","volume":"29","author":"De Caluw\u00e9","year":"2021","journal-title":"Trends Microbiol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virol.2007.07.012","article-title":"Venezuelan equine encephalitis virus infection of mosquito cells requires acidification as well as mosquito homologs of the endocytic proteins Rab5 and Rab7","volume":"369","author":"Colpitts","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0170","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3245","article-title":"On the entry of an emerging arbovirus into host cells: Mayaro virus takes the highway to the cytoplasm through fusion with early endosomes and caveolae-derived vesicles","volume":"5","author":"Carvalho","year":"2017","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0175","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02731-19","article-title":"Encephalitic alphaviruses exploit caveola-mediated transcytosis at the blood-brain barrier for central nervous system entry","volume":"11","author":"Salimi","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/249640","article-title":"Replication of alphaviruses: a review on the entry process of alphaviruses into cells","volume":"2011","author":"Leung","year":"2011","journal-title":"Adv. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165307","article-title":"Entry receptors\u2014the gateway to alphavirus infection","volume":"133","author":"Zimmerman","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125514_bb0190","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/v15051163","article-title":"Interactions of equine viruses with the host kinase machinery and implications for one health and human disease","volume":"15","author":"Anderson","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0195","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virol.2016.06.005","article-title":"Host translation shutoff mediated by non-structural protein 2 is a critical factor in the antiviral state resistance of Venezuelan equine encephalitis virus","volume":"496","author":"Bhalla","year":"2016","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0200","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/v15020413","article-title":"Advances in the development of small molecule antivirals against equine encephalitic viruses","volume":"15","author":"Ogorek","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105588","article-title":"Importin \u03b1\/\u03b2-dependent nuclear transport of human parvovirus B19 nonstructural protein 1 is essential for viral replication","volume":"213","author":"Alvisi","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105560","article-title":"Venezuelan equine encephalitis virus E1 protein interacts with PDIA6 and PDI inhibition reduces alphavirus production","volume":"212","author":"Panny","year":"2023","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011179","article-title":"The alphavirus nonstructural protein 2 NTPase induces a host translational shut-off through phosphorylation of eEF2 via cAMP-PKA-eEF2K signaling","volume":"19","author":"Treffers","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104883","article-title":"Mutations on VEEV nsP1 relate RNA capping efficiency to ribavirin susceptibility","volume":"182","author":"Rabah","year":"2020","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.125514_bb0225","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acsmedchemlett.0c00215","article-title":"Vinyl sulfone-based inhibitors of nonstructural protein 2 block the replication of Venezuelan equine encephalitis virus","volume":"11","author":"Zhang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.antiviral.2019.02.001","article-title":"Proteolytic cleavage of host proteins by the Group IV viral proteases of Venezuelan equine encephalitis virus and Zika virus","volume":"164","author":"Morazzani","year":"2019","journal-title":"Antivir. Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.125514_bb0235","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/JVI.03142-12","article-title":"Venezuelan equine encephalitis virus nsP2 protein regulates packaging of the viral genome into infectious virions","volume":"87","author":"Kim","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105494","article-title":"Targeting the alphavirus virus replication process for antiviral development","volume":"210","author":"Tan","year":"2023","journal-title":"Antivir. Res."},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.125514_bb0245","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrmicro1006","article-title":"Transmission cycles, host range, evolution and emergence of arboviral disease","volume":"2","author":"Weaver","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cveq.2022.11.007","article-title":"Eastern, Western, and Venezuelan equine encephalitis and West Nile viruses: clinical and public health considerations","volume":"39","author":"Luethy","year":"2023","journal-title":"Vet. Clin. Equine Pract."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/v15010005","article-title":"In vitro and in vivo phenotypes of Venezuelan, eastern and western equine encephalitis viruses derived from cDNA clones of human isolates","volume":"15","author":"Gardner","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0260","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0265","doi-asserted-by":"crossref","unstructured":"E.E. Coates, S. Edupuganti, G.L. Chen, M. Happe, L. Strom, A. Widge, M.B. Florez, J.H. Cox, I. Gordon, S. Plummer, A. Ola, G. Yamshchikov, C. Andrews, S. Curate-Ingram, P. Morgan, S. Nagar, M.H. Collins, A. Bray, T. Nguyen, J. Stein, C.L. Case, F. Kaltovich, D. Wycuff, C.J. Liang, K. Carlton, S. Vazquez, J.R. Mascola, J.E. Ledgerwood, E. Butler, J. Winter, J. Xu, A. Sherman, C. Kelley, R. Fredrick, N. Rouphael, V. Phadke, C. Whitney, A. Alvarez, R. Dennis, R. Fineman, P. Lankford-Turner, S. Yi, L. Lai, G. Burch, S. Gupta, N. Berkowitz, C. Carter, A. Beck, B. Larkin, S. Taylor, M. Alger, J. Bahorich, A. Lynch Chamberlain, Y.-c. Chang, R. Chaudhuri, J. Cooper, J. Demirji, F. Yang, A. Fernald, D. Gollapudi, J. Holland-Linn, L. Kueltzo, J. Lee, J. Liu, X. Liu, R. Mowery, S. O'Connell, E. Rosales-Zavala, J. Sands, X. Wang, S. Weng, S. Witter, Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial, Lancet Infect. Dis. 22(8) (2022) 1210\u20131220.","DOI":"10.1016\/S1473-3099(22)00052-4"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0270","first-page":"1","article-title":"Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis","volume":"12","author":"Liu","year":"2022","journal-title":"Sci. Rep."},{"issue":"31","key":"10.1016\/j.ijbiomac.2023.125514_bb0275","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1016\/j.vaccine.2009.04.049","article-title":"Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine","volume":"27","author":"Dupuy","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/pathogens11020271","article-title":"Methods of inactivation of highly pathogenic viruses for molecular, serology or vaccine development purposes","volume":"11","author":"Elveborg","year":"2022","journal-title":"Pathogens"},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0285","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0290","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jviromet.2018.01.009","article-title":"Evaluation of the inactivation of Venezuelan equine encephalitis virus by several common methods","volume":"254","author":"Patterson","year":"2018","journal-title":"J. Virol. Methods"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0295","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbrc.2007.04.115","article-title":"Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide","volume":"358","author":"Sharma","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.125514_bb0300","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.4161\/hv.25602","article-title":"Dengue virus photo-inactivated in presence of 1, 5-iodonaphthylazide (INA) or AMT, a psoralen compound (4\u2032-aminomethyl-trioxsalen) is highly immunogenic in mice","volume":"9","author":"Raviprakash","year":"2013","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"18","key":"10.1016\/j.ijbiomac.2023.125514_bb0305","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.vaccine.2010.02.056","article-title":"Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0310","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jviromet.2009.11.006","article-title":"A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV)","volume":"163","author":"Fine","year":"2010","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0315","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for Venezuelan equine encephalitis","volume":"27","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fitd.2022.813671","article-title":"Live-attenuated VEEV vaccine delivered by iDNA using microneedles is immunogenic in rabbits","volume":"3","author":"Tretyakova","year":"2022","journal-title":"Front. Trop. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0325","doi-asserted-by":"crossref","first-page":"13990","DOI":"10.1038\/s41598-018-32033-w","article-title":"Lipid-coated mesoporous silica nanoparticles for the delivery of the ML336 antiviral to inhibit encephalitic alphavirus infection","volume":"8","author":"LaBauve","year":"2018","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.125514_bb0330","doi-asserted-by":"crossref","first-page":"2001812","DOI":"10.1002\/adhm.202001812","article-title":"Next-generation vaccines: nanoparticle-mediated dna and mrna delivery","volume":"10","author":"Ho","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009306","article-title":"The transcriptional landscape of Venezuelan equine encephalitis virus (TC-83) infection","volume":"15","author":"Yao","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"24","key":"10.1016\/j.ijbiomac.2023.125514_bb0340","doi-asserted-by":"crossref","first-page":"13552","DOI":"10.1128\/JVI.01576-07","article-title":"Analysis of Venezuelan equine encephalitis virus capsid protein function in the inhibition of cellular transcription","volume":"81","author":"Garmashova","year":"2007","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0345","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/21505594.2018.1509668","article-title":"Direct and indirect pro-inflammatory cytokine response resulting from TC-83 infection of glial cells","volume":"9","author":"Keck","year":"2018","journal-title":"Virulence"},{"issue":"25","key":"10.1016\/j.ijbiomac.2023.125514_bb0350","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.ijbiomac.2023.125514_bb0355","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1016\/j.vaccine.2004.12.023","article-title":"Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus","volume":"23","author":"Reed","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0360","article-title":"Venezuelan equine encephalitis virus V3526 vaccine RNA-Dependent RNA polymerase mutants increase vaccine safety through restricted tissue tropism in a murine model","volume":"2","author":"Haines","year":"2022","journal-title":"Zoonoses (Burlington, Mass.)"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0365","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ymthe.2018.12.013","article-title":"Self-amplifying RNA vaccines for Venezuelan equine encephalitis virus induce robust protective immunogenicity in mice","volume":"27","author":"Samsa","year":"2019","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0370","article-title":"Rationally attenuated vaccines for Venezuelan equine encephalitis protect against epidemic strains with a single dose","volume":"8","author":"Rossi","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"10384","key":"10.1016\/j.ijbiomac.2023.125514_bb0375","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(23)00048-X","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial","volume":"401","author":"Tschismarov","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0380","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164946","article-title":"Recombinant vesicular stomatitis virus\u2013vectored vaccine induces long-lasting immunity against Nipah virus disease","volume":"133","author":"Woolsey","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0385","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41541-022-00543-4","article-title":"Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines","volume":"7","author":"Ebenig","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0390","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12917-022-03529-5","article-title":"A recombinant capripoxvirus expressing the F protein of peste des petits ruminants virus and the P12A3C of foot-and-mouth disease virus","volume":"19","author":"Li","year":"2023","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0395","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.virol.2022.12.010","article-title":"Mucosal immune responses induced by oral administration of recombinant Lactococcus lactis expressing the S1 protein of PDCoV","volume":"578","author":"Zhai","year":"2023","journal-title":"Virology"},{"issue":"18","key":"10.1016\/j.ijbiomac.2023.125514_bb0400","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.vaccine.2023.03.055","article-title":"Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses","volume":"41","author":"Criado","year":"2023","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.ijbiomac.2023.125514_bb0405","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1128\/JVI.77.17.9278-9286.2003","article-title":"Recombinant sindbis\/Venezuelan equine encephalitis virus is highly attenuated and immunogenic","volume":"77","author":"Paessler","year":"2003","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0410","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1128\/JVI.80.6.2784-2796.2006","article-title":"Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN\/VEE viruses","volume":"80","author":"Paessler","year":"2006","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.ijbiomac.2023.125514_bb0415","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1016\/j.vaccine.2020.02.007","article-title":"Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge","volume":"38","author":"Tretyakova","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0420","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.biori.2017.10.001","article-title":"The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches","volume":"1","author":"Jorge","year":"2017","journal-title":"Biotechnol. Res. Innov."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0425","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral vectors as vaccine carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-6-118","article-title":"Improved efficacy of a gene optimised adenovirus-based vaccine for Venezuelan equine encephalitis virus","volume":"6","author":"Williams","year":"2009","journal-title":"Virol. J."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.125514_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002197","article-title":"IRES-driven expression of the capsid protein of the Venezuelan equine encephalitis virus TC-83 vaccine strain increases its attenuation and safety","volume":"7","author":"Guerbois","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0445","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01274-17","article-title":"Novel insect-specific Eilat virus-based chimeric vaccine candidates provide durable, mono-and multivalent, single-dose protection against lethal alphavirus challenge","volume":"92","author":"Erasmus","year":"2018","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125514_bb0450","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0264-410X(99)00271-6","article-title":"DNA and RNA-based vaccines: principles, progress and prospects","volume":"18","author":"Leitner","year":"1999","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13952","article-title":"An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines","volume":"9","author":"Hillary","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0460","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41564-020-00815-6","article-title":"A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model","volume":"6","author":"Hawman","year":"2021","journal-title":"Nat. Microbiol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0465","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ymthe.2022.09.016","article-title":"Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model","volume":"31","author":"Hawman","year":"2023","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0470","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.vaccine.2022.12.067","article-title":"Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice","volume":"41","author":"Jang","year":"2023","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0475","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"17","key":"10.1016\/j.ijbiomac.2023.125514_bb0480","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2008.02.033","article-title":"The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0485","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/vaccines11020280","article-title":"Improved DNA vaccine delivery with needle-free injection systems","volume":"11","author":"Ledesma-Feliciano","year":"2023","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28484","article-title":"Needle-free injection system delivery of ZyCoV-D DNA vaccine demonstrated improved immunogenicity and protective efficacy in rhesus macaques against SARS-CoV-2","volume":"95","author":"Yadav","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0495","series-title":"DNA Vaccines: Methods and Protocols","first-page":"83","article-title":"Needle-free injection of DNA vaccines: a brief overview and methodology","author":"Raviprakash","year":"2006"},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.125514_bb0500","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00027-18","article-title":"Development of a broadly accessible Venezuelan equine encephalitis virus replicon particle vaccine platform","volume":"92","author":"Agnihothram","year":"2018","journal-title":"J. Virol."},{"issue":"25","key":"10.1016\/j.ijbiomac.2023.125514_bb0505","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.vaccine.2019.04.072","article-title":"Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome","volume":"37","author":"Tretyakova","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0510","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.omtm.2020.04.009","article-title":"Nanoplasmid vectors co-expressing innate immune agonists enhance DNA vaccines for venezuelan equine encephalitis virus and ebola virus","volume":"17","author":"Suschak","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"25\u201326","key":"10.1016\/j.ijbiomac.2023.125514_bb0515","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/S0264-410X(03)00362-1","article-title":"Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus","volume":"21","author":"Riemenschneider","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0520","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41541-022-00469-x","article-title":"A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge","volume":"7","author":"Suschak","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0525","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8521060","volume":"2018","author":"Dupuy","year":"2018","journal-title":"J Immunol Res"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125514_bb0530","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0535","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front. Microbiol."},{"issue":"492","key":"10.1016\/j.ijbiomac.2023.125514_bb0540","doi-asserted-by":"crossref","first-page":"eaav3113","DOI":"10.1126\/scitranslmed.aav3113","article-title":"A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates","volume":"11","author":"Ko","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0545","first-page":"1","article-title":"Multi-pathogen based chimeric vaccine to fight against COVID-19 and concomitant coinfections","author":"Ojha","year":"2023","journal-title":"Biotechnol. Lett."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12934-020-01394-1","article-title":"Design and development of a chimeric vaccine candidate against zoonotic hepatitis E and foot-and-mouth disease","volume":"19","author":"Behloul","year":"2020","journal-title":"Microb. Cell Factories"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0555","doi-asserted-by":"crossref","first-page":"e03613","DOI":"10.1128\/spectrum.03613-22","article-title":"Insect-specific chimeric viruses potentiated antiviral responses and inhibited pathogenic alphavirus growth in mosquito cells","volume":"11","author":"Tan","year":"2023","journal-title":"Microbiol. Spectr."},{"issue":"23\u201324","key":"10.1016\/j.ijbiomac.2023.125514_bb0560","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/S0264-410X(99)00142-5","article-title":"Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy","volume":"17","author":"Caley","year":"1999","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.ijbiomac.2023.125514_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002709","article-title":"Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats","volume":"3","author":"Kamrud","year":"2008","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0570","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated venezuelan equine encephalitis virus: expression of heterologous genesin vitroand immunization against heterologous pathogensin vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0575","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.ijbiomac.2023.125514_bb0580","first-page":"7861","article-title":"Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA","volume":"61","author":"Velders","year":"2001","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.125514_bb0585","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1128\/JVI.01566-09","article-title":"A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles","volume":"84","author":"Pan","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0590","doi-asserted-by":"crossref","unstructured":"Y.-N. Zhang, C. Chen, C.-L. Deng, C.-g. Zhang, N. Li, Z. Wang, L. Zhao, B. Zhang, A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-rabies replicon, EBioMedicine 56 (2020) 102819.","DOI":"10.1016\/j.ebiom.2020.102819"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0595","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/22221751.2022.2030198","article-title":"A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon","volume":"11","author":"Li","year":"2022","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0600","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0610","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/IAI.71.3.1491-1496.2003","article-title":"Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge","volume":"71","author":"Lee","year":"2003","journal-title":"Infect. Immun."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.125514_bb0615","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/339677","article-title":"Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon","volume":"185","author":"Lee","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.738082","article-title":"Study on the characteristic codon usage pattern in porcine epidemic diarrhea virus genomes and its host adaptation phenotype","volume":"12","author":"Si","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0625","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ijbiomac.2022.09.179","article-title":"Deep decoding of codon usage strategies and host adaption preferences of soybean mosaic virus","volume":"222","author":"Jiang","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"9\u201310","key":"10.1016\/j.ijbiomac.2023.125514_bb0630","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00239-021-10027-z","article-title":"Codon usage bias: an endless tale","volume":"89","author":"Iriarte","year":"2021","journal-title":"J. Mol. Evol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2019.113806","article-title":"Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design","volume":"277","author":"Sheikh","year":"2020","journal-title":"J. Virol. Methods"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103682","article-title":"Distinct codon usage bias evolutionary patterns between weakly and strongly virulent respiratory viruses","volume":"25","author":"Chen","year":"2022","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0645","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41559-020-1124-7","article-title":"Dissimilation of synonymous codon usage bias in virus\u2013host coevolution due to translational selection","volume":"4","author":"Chen","year":"2020","journal-title":"Nat. Ecol. Evol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0650","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12864-021-07559-5","article-title":"Effect of genome composition and codon bias on infectious bronchitis virus evolution and adaptation to target tissues","volume":"22","author":"Franzo","year":"2021","journal-title":"BMC Genomics"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125514_bb0655","doi-asserted-by":"crossref","first-page":"evab106","DOI":"10.1093\/gbe\/evab106","article-title":"Transcription, mRNA export, and immune evasion shape the codon usage of viruses","volume":"13","author":"Mordstein","year":"2021","journal-title":"Genome Biol. Evol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0660","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3389\/fcell.2020.00831","article-title":"SARS-CoV-2 codon usage bias downregulates host expressed genes with similar codon usage","volume":"8","author":"Alonso","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0665","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001836","article-title":"Codon pair bias deoptimization of essential genes in infectious laryngotracheitis virus reduces protein expression","volume":"104","author":"Vaz","year":"2023","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106280","article-title":"Coronavirus accessory protein ORF3 biology and its contribution to viral behavior and pathogenesis","volume":"26","author":"Si","year":"2023","journal-title":"iScience"},{"issue":"21","key":"10.1016\/j.ijbiomac.2023.125514_bb0675","doi-asserted-by":"crossref","first-page":"10762","DOI":"10.1128\/JVI.01443-15","article-title":"Generation of live attenuated influenza virus by using codon usage bias","volume":"89","author":"Fan","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.633946","article-title":"Codon usage and adenovirus fitness: implications for vaccine development","volume":"12","author":"Gim\u00e9nez-Roig","year":"2021","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.125514_bb0685","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/vaccines11020391","article-title":"Influenza virus carrying a codon-reprogrammed neuraminidase gene as a strategy for live attenuated vaccine","volume":"11","author":"Dong","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199081","article-title":"Codon usage bias of Venezuelan equine encephalitis virus and its host adaption","volume":"328","author":"Wang","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0695","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.1071097","article-title":"Analysis of codon usage bias of lumpy skin disease virus causing livestock infection","volume":"9","author":"Rahman","year":"2022","journal-title":"Front. Vet. Sci."},{"issue":"21","key":"10.1016\/j.ijbiomac.2023.125514_bb0700","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1128\/JVI.01323-08","article-title":"Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis","volume":"82","author":"Gardner","year":"2008","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.ijbiomac.2023.125514_bb0705","doi-asserted-by":"crossref","first-page":"10571","DOI":"10.1128\/JVI.01041-09","article-title":"Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff","volume":"83","author":"Simmons","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2023.125514_bb0710","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fmicb.2017.00081","article-title":"Live, attenuated Venezuelan equine encephalitis virus vaccine (TC83) causes persistent brain infection in mice with non-functional \u03b1\u03b2 T-cells","volume":"8","author":"Taylor","year":"2017","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2023.125514_bb0715","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2012.12.050","article-title":"Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine","volume":"31","author":"Tretyakova","year":"2013","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.ijbiomac.2023.125514_bb0720","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0264-410X(98)00315-6","article-title":"TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus","volume":"17","author":"Phillpotts","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0725","doi-asserted-by":"crossref","first-page":"vey004","DOI":"10.1093\/ve\/vey004","article-title":"Low-fidelity Venezuelan equine encephalitis virus polymerase mutants to improve live-attenuated vaccine safety and efficacy","volume":"4","author":"Kautz","year":"2018","journal-title":"Virus Evol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.125514_bb0730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-020-00241-z","article-title":"Engineering a fidelity-variant live-attenuated vaccine for chikungunya virus","volume":"5","author":"Weiss","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0735","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coviro.2012.02.014","article-title":"Nonhuman primate models of encephalitic alphavirus infection: historical review and future perspectives","volume":"2","author":"Dupuy","year":"2012","journal-title":"Curr. Opin. Virol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.125514_bb0740","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/JVI.03361-12","article-title":"Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus","volume":"87","author":"Herbert","year":"2013","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.125514_bb0745","article-title":"Opportunities for refinement of non-human primate vaccine studies","volume":"9","author":"Prescott","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.125514_bb0750","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hast.580","article-title":"The ethics of infection challenges in primates","volume":"46","author":"Barnhill","year":"2016","journal-title":"Hast. Cent. Rep."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.125514_bb0755","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41577-018-0005-7","article-title":"Nonhuman primate models of human viral infections","volume":"18","author":"Estes","year":"2018","journal-title":"Nat. Rev. Immunol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302302408X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302302408X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T19:06:39Z","timestamp":1727463999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014181302302408X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":151,"alternative-id":["S014181302302408X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125514","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A roadmap for developing Venezuelan equine encephalitis virus (VEEV) vaccines: Lessons from the past, strategies for the future","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"125514"}}